| 370.16 50.93 (15.95%) | 08-06 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 446.8 |
1-year : | 521.87 |
| Resists | First : | 382.54 |
Second : | 446.8 |
| Pivot price | 314.64 |
|||
| Supports | First : | 324.07 |
Second : | 287.93 |
| MAs | MA(5) : | 322.55 |
MA(20) : | 315.67 |
| MA(100) : | 314.67 |
MA(250) : | 241.47 |
|
| MACD | MACD : | 4.1 |
Signal : | 0.6 |
| %K %D | K(14,3) : | 71.3 |
D(3) : | 58.2 |
| RSI | RSI(14): 67.9 |
|||
| 52-week | High : | 382.54 | Low : | 37.18 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ PRAX ] has closed Bollinger Bands are 5.6% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 383 - 384.47 | 384.47 - 385.94 |
| Low: | 342.78 - 344.43 | 344.43 - 346.07 |
| Close: | 367.37 - 370.02 | 370.02 - 372.67 |
Praxis Precision Medicines, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to creating innovative treatments for central nervous system (CNS) conditions that stem from an imbalance in neuronal activity. The company's primary investigational compounds currently undergoing evaluation include: PRAX-114, an extrasynaptic-preferring positive allosteric modulator of the GABAA receptor, which is currently in Phase IIa clinical trials for addressing both major depressive disorder and perimenopausal depression. Additionally, PRAX-944, a small molecule designed to selectively inhibit T-type calcium channels, is also progressing through Phase IIa clinical trials to manage essential tremor. Beyond these, Praxis is also advancing a pipeline of other promising drug candidates, such as: PRAX-562, a persistent sodium current blocker, undergoing Phase I clinical evaluation for treating severe pediatric epilepsy and adult cephalgia (headaches). PRAX-222, an antisense oligonucleotide (ASO) aimed at individuals suffering from gain-of-function (GOF) SCN2A epilepsy. And a program targeting KCNT1 for the treatment of KCNT1 GOF epilepsy. To further its research and development efforts, Praxis maintains several strategic alliances. These include a cooperation and licensing arrangement with RogCon Inc.; a licensing deal with Purdue Neuroscience Company; a comprehensive research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and a collaborative project with The Florey Institute focused on the creation of three new antisense oligonucleotides (ASOs). Established in 2015, the company's headquarters are situated in Boston, Massachusetts.
Thu, 06 Aug 2026
Praxis Precision Medicines Inc (PRAX) (Q2 2026) Earnings Call Highlights: FDA Approvals on ... - Yahoo! Finance Canada
Thu, 06 Aug 2026
Earnings Flash (PRAX) Praxis Precision Medicines Posts Q2 Loss $2.87 a Share, vs. FactSet Est of $3.64 Loss - marketscreener.com
Thu, 06 Aug 2026
Praxis Precision Medicines beats Q2 loss estimates; shares rise By Investing.com - Investing.com South Africa
Thu, 06 Aug 2026
Praxis Precision Medicines, Inc. (PRAX) stock price, news, quote and history - Yahoo Finance Australia
Thu, 06 Aug 2026
Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2026 Financial Results - Yahoo Finance
Tue, 04 Aug 2026
29 New Praxis Employees Get Stock Units, Four-Year Vesting - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 28 (M) |
| Shares Float | 24 (M) |
| Held by Insiders | 0.2 (%) |
| Held by Institutions | 117.5 (%) |
| Shares Short | 3,760 (K) |
| Shares Short P.Month | 3,570 (K) |
| EPS | -13.4 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 50.61 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -23.1 % |
| Return on Equity (ttm) | -35.4 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -10.2 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -12.82 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -282 (M) |
| Levered Free Cash Flow | -176 (M) |
| PE Ratio | -27.65 |
| PEG Ratio | 0 |
| Price to Book value | 7.31 |
| Price to Sales | 0 |
| Price to Cash Flow | -36.57 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|